Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Next Previous
X
Search
Trial Profile

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoid leukaemia; Richter's syndrome; T-cell prolymphocytic leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Acerta Pharma

    • Most Recent Events

    • 29 Nov 2023 According to an AstraZeneca media release, analysis of 5 studies (CL-001, CL-003, CL-006, CL-007 & CL-309) showing acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL will be presented at 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
    • 14 Jul 2023 Planned End Date changed from 15 Jul 2026 to 6 Sep 2027.
    • 13 Dec 2022 Final results of treatment naive cohort were presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top